Maintenance of mammary functional capacity during cycles of proliferation and regression depends on appropriate cell fate decisions of mammary progenitor cells to populate an epithelium consisting of secretory luminal cells and contractile myoepithelial cells. It is well established that transforming growth factor-b (TGFb) restricts mammary epithelial cell proliferation and that sensitivity to TGFb is decreased in breast cancer. We show that TGFb also exerts control of mammary progenitor self-renewal and lineage commitment decisions by stringent regulation of breast cancer associated 1 (BRCA1), which controls stem cell self-renewal and lineage commitment. Either genetic depletion of Tgfb1 or transient blockade of TGFb increased self-renewal of mammary progenitor cells in mice, cultured primary mammary epithelial cells, and also skewed lineage commitment toward the myoepithelial fate. TGFb stabilized the abundance of BRCA1 by reducing the abundance of microRNA-182 (miR-182). Ectopic expression of BRCA1 or antagonism of miR-182 in cultured TGFb-deficient mammary epithelial cells restored luminal lineage commitment. These findings reveal that TGFb modulation of BRCA1 directs mammary epithelial cell fate and, because stem or progenitor cells are thought to be the cell of origin for aggressive breast cancer subtypes, suggest that TGFb dysregulation during tumorigenesis may promote distinct breast cancer subtypes.
INTRODUCTION
Transforming growth factor-b (TGFb) is a pluripotent cytokine that plays multiple roles in mammary development and breast carcinogenesis (1). Silberstein and Daniel (2) first showed that pellets containing TGFb profoundly inhibit mammary epithelial proliferation. Subsequent genetic depletion of Tgfb1 in mice confirmed this finding by demonstrating significant acceleration of ductal morphogenesis during puberty and increased proliferation of both hormone receptor-positive and hormone receptor-negative luminal cells as a function of ovarian hormones during proliferative stages of the estrus cycle (3, 4) . In contrast, overexpression of active TGFb alters differentiation and induces replicative senescence (5, 6) . Studies in mammary gland and other tissues suggest that TGFb is involved in stem cell functions, including cell fate decisions, cell cycle entry, self-renewal, and niche formation (1, (7) (8) (9) .
The development of the mouse mammary anlage in utero and ductal morphogenesis during puberty give rise to luminal cells that respond to hormonal stimulation to proliferate and undergo secretory differentiation during pregnancy, followed by marked involution upon weaning. Luminal cells are supported by a basal layer consisting of myoepithelial cells that perform contractile function during lactation. Thus, this dynamic organ engages multiple endocrine systems to orchestrate cycles of differentiation, functional maturation to produce milk, and regression to a quiescent state. Delineation of the mammary epithelial hierarchy is essential for understanding the complex development, maturation, and cyclical secretory differentiation of the breast (10) .
The epithelium harbors mammary stem cells (MaSCs) that provide the marked regenerative capacity of the organ. The regenerative capability of MaSCs is astounding; a single mammary gland stem cell is predicted to be capable of generating 10 12 to 10 13 progeny (11) . Although a single MaSC can give rise to an entire mammary epithelial tree in mice, this capability appears to be restricted in situ. Two fundamental properties define MaSCs: (i) the ability to self-renew through symmetric division to maintain a pool of stem cells and (ii) multipotency that confers the potential by asymmetric division to generate differentiated daughter cells. Analysis of self-renewal and lineage commitment using mammary repopulating activity (12, 13) and lineage tracing (14, 15) provides strong evidence for MaSCs, albeit with varying degrees of functional capacity to recapitulate the mammary hierarchy. Although most current research focuses on identifying features of discrete MaSCs, the functional potential of the tissue depends on appropriate cell fate decisions to maintain homeostasis of a relatively quiescent ductal system during repeated ovarian cycles.
Unraveling the mechanisms that regulate the mammary epithelial lineage is important not only for elucidating how homeostasis is maintained but also in the etiology of breast cancer because the cell-of-origin hypothesis posits that certain breast cancers arise from transformation of stem or progenitor cells (16) . The expression profiles of basal-like and claudin-low intrinsic breast cancer subtypes are enriched in the signatures of MaSCs and progenitor cells (17) , and mutations in the gene for breast cancer-associated 1 (BRCA1) cause dysregulation of MaSCs and luminal progenitors (18) (19) (20) and predispose the gland to develop aggressive hormone receptor-negative breast cancer. TGFb biology appears to discriminate between these two subtypes (16, 21, 22) . Here, we show that TGFb controls mammary self-renewal and lineage commitment during homeostasis through stringent regulation of BRCA1 by means of a microRNA (miRNA)-mediated mechanism.
RESULTS

TGFb1 depletion promotes self-renewal in mammary gland
Overexpression of constitutively active TGFb1 in the mammary gland decreases mammary repopulating activity (7) . We first sought to investigate the effect of TGFb depletion on this process. Hence, we evaluated serial transplantation efficiency of the mammary glands of BALB/c Tgfb1 wild-type (WT) and heterozygous (HT) littermates. TGFb1 protein is reduced by 70 to 90% in tissue extracts from Tgfb1 HT mice relative to that in tissue extracts from WT mice (3). Transplants of fragments from Tgfb1 HT mice generated more outgrowths and had greater serial transplantation capacity than did WT mammary epithelial cells (MECs) (fig. S1, A and B), which indicate greater self-renewal capacity. The repopulation capacity of isolated MECs from Tgfb1 HT and WT mice was then assessed with a limiting dilution assay that determines the frequency of MECs capable of recapitulating mammary morphogenesis when inoculated into fat pads divested of endogenous epithelium (23) . The repopulating capacity of Tgfb1 HT MECs was threefold greater than that of WT MEC (1 of 1500 and 1 of 4712, respectively; Fig. 1A ). Next, we used flow cytometry to evaluate Lin − /CD24 med /CD49f high (12) or CD29 high CD24 high CD61 + (17) , two sets of cell surface markers of MEC populations shown to be enriched in mammary repopulating activity ( fig. S2 ). Compared to those from WT mice, the MEC prepared from adult Tgfb1 HT mice had about twofold more cells that exhibited MaSC surface markers (Fig. 1, B and C) . Consistent with this, quantitative transcript analysis revealed that the stem cell genes Notch1 and Procr were increased 3.4-fold and Prc2 was increased 7-fold in RNA from Tgfb1 HT MECs compared to WT MECs (Fig. 1D ). These data support the idea that TGFb inhibits MaSC expansion.
Mammosphere formation by cells cultured under restricted growth factor conditions is a surrogate of repopulating capacity (24) . Tgfb1 HT and WT MECs were sorted using the cell surface markers CD29, CD24, and CD61 to define populations enriched in MaSCs ) and seeded into mammosphere culture conditions (24) . After 7 days, the characteristics of each sorted population were assessed. As described, cells sorted from the CD29 low CD24 − fraction did not form multicellular colonies. Acinar structures evidenced by hollow lumen were obtained from cells sorted from the CD29 low CD24 + CD61 + fraction, whereas solid-appearing mammospheres thought to represent MaSCs were obtained from the CD29 high CD24 +
CD61
+ fraction. Similar to the increase in in vivo repopulating activity, we conducted a limiting dilution assay based on the formation of solid mammospheres ( fig. S3 ). The mammosphere forming efficiency (MFE) was increased 2.5-fold from Tgfb1 HT MECs compared to WT MECs (Fig. 1E) . Consistent with TGFb's role in inhibiting proliferation (3), Tgfb1 HT MEC-derived mammospheres were significantly larger compared to those derived from WT MECs [97.0 ± 5.5 (n = 12) versus 76.3 ± 4.8 (n = 10); P < 0.05].
MaSCs established during development are susceptible to physiological mediators of expansion, as is evident during pregnancy (10) . To test whether decreased TGFb activity during development alters the frequency of MaSCs or constitutively inhibits MaSC self-renewal, we treated BALB/c mice with TGFb pan-isoform neutralizing monoclonal antibodies, 1D11, or isotype-matched immunoglobulin G1 (IgG1) control antibodies twice a week for 4 weeks. Compared to control-treated mice, the mammary epithelium of mice treated with neutralizing antibodies exhibited significantly less phosphorylation of the TGFb effector SMAD2 (p-SMAD2; fig. S4 ). The fraction of CD29 high CD24 high CD61 + MEC isolated from mice treated with 1D11 was increased twofold, similar to the difference seen between WT MECs and Tgfb1 HT MECs (Fig. 1F) . Because the neutralizing antibody captures ligand released from extracellular stores, these data suggest that TGFb activity dynamically restricts MaSC self-renewal.
To test the idea that autocrine TGFb is necessary to restrain selfrenewal, we treated mammospheres from primary MECs for 1 week with 1D11 or a small-molecule inhibitor of TGFb type I receptor kinase, LY364947. Dissociated mammospheres from treated or control cultures were placed into secondary passage to test MFE without further treatment. Both ligand capture by 1D11 (Fig. 1G ) and receptor signaling blockade by LY364947 (Fig. 1H ) resulted in a more than twofold increase in mammosphere formation ( fig. S3 ). Together, these data indicate that autocrine TGFb activity inhibits MaSC self-renewal.
TGFb1 depletion skews lineage commitment
We noticed that the CD24 + /CD49f med population, which is enriched in myoepithelial cells, was significantly increased in MECs isolated from Tgfb1 HT mice ( Fig. 2A) . To confirm this, we conducted flow cytometry analysis using cytokeratin 14 (K14) and cytokeratin 18 (K18), which mark myoepithelial and luminal populations, respectively. More K14 + cells were obtained from Tgfb1 HT MECs (Fig. 2B ). This expansion was at the expense of K18 + luminal MECs from Tgfb1 HT mice compared to WT mice (Fig. 2C ). The protein p63 is expressed only in basal MECs, which are primarily myoepithelial. The percentage of p63 + myoepithelial cells was significantly increased in tissue from Tgfb1 HT mice compared to WT mice (Fig. 2D ). This was also evident in the mammary glands of mice treated with the TGFb neutralizing antibody 1D11 (Fig. 2E ). Because proliferation is increased in the mammary glands of Tgfb1 HT mice (4), we investigated whether proliferation was increased specifically in myoepithelial cells by assessing the colocalization of the proliferation marker Ki-67 and p63 by immunostaining. The frequency of Ki-67 and p63 double-positive cells did not significantly increase in tissue from either Tgfb1 HT mice or 1D11-treated mice (Fig. 2, D and E). Together, these data suggested that TGFb depletion skews lineage commitment toward basal cells.
We next examined mammosphere composition as a function of TGFb depletion by immunostaining for the myoepithelial marker p63 (Fig. 3A) . Relative to their respective controls, the p63 + population was increased in mammospheres derived from Tgfb1 HT MECs (Fig. 3C ), secondary mammospheres treated with 1D11 TGFb neutralizing antibody (Fig. 3D) , and secondary mammospheres treated with the small-molecule TGFb type I receptor kinase inhibitor LY364947 (Fig. 3E ). The proportion of K14 + cells in mammospheres also appeared to increase in these three TGFb-compromised models (Fig. 3B) . Thus, we concluded that TGFb depletion also skews epithelial lineage commitment toward myoepithelial differentiation.
The TGFb1-BRCA1 axis restricts MaSC self-renewal BRCA1 mutations expand MaSCs and luminal progenitors in human cells and tissues (18) (19) (20) . We have previously reported that Brca1 mRNA is decreased in murine Tgfb1 null keratinocytes compared to HT keratinocytes, and that BRCA1 abundance is decreased in cultured human epithelial cells treated with a small-molecule TGFb type 1 receptor kinase inhibitor (25) ; moreover, Brca1 mRNA is also significantly decreased in gene expression microarrays of mammary glands from Tgfb1 HT mice compared to WT mice (21) .
Thus, we examined the abundance of BRCA1 protein and mRNA in MECs from Tgfb1 HT mice compared to those from WT mice. Both protein and message abundance were decreased in Tgfb1 HT MECs (Fig. 4 , A and B). BRCA1 expression is tightly regulated during cell cycle progression in many cell types and is increased during the S phase (26, 27) . To examine this response in more detail, we used MCF10A cells, a nonmalignant human MEC line, treated with LY364947 to inhibit TGFb signaling. BRCA1 protein rapidly increased in response to TGFb; concomitant treatment with LY364957 blocked this effect. Effective suppression of TGFb signaling by LY364947 was evident by inhibition of TGFb-induced p-SMAD2 ( fig. S5 ). Both protein and mRNA abundance were further decreased with prolonged inhibition (Fig. 4C ). The amount of BRCA1 mRNA in LY364947-treated MCF10A cells was comparable to that in SUM1315 cells, which is a BRCA1 haploinsufficient breast cancer cell line (Fig. 4D) . Likewise, treatment of MCF10A with TGFb neutralizing antibody similarly decreased BRCA1 protein and mRNA (Fig. 4 , E and F). Because BRCA1 is increased during the S phase, and inhibition of TGFb signaling increases proliferation in MCF10A cells, BRCA1 would be expected to increase if due to cell cycle rather than to decrease, as observed. Moreover, TGFb treatment of MCF10A increased BRCA1 mRNA (Fig. 4G) . Together, these data indicate discrete regulation of BRCA1 by TGFb. Given that BRCA1 mutations alter human mammary lineage commitment (20), we next tested whether overexpressing Brca1 in Tgfb1 HT MECs could reverse the effect of TGFb on mammary lineage. BRCA1 protein abundance increased in Tgfb1 HT MECs infected with the Brca1-expressing lentivirus compared to those infected with an empty vector (Fig. 5A) . Functional evaluation of lentiviral BRCA1 overexpression in Tgfb1 HT MECs compared to Tgfb1 HT MECs expressing the empty vector resulted in more than threefold decrease in mammosphere forming capacity, which was similar to that of WT mammospheres (Fig. 5B) . Although Tgfb1 HT mammospheres contain more p63 + cells than Tgfb1 WT mammospheres, their frequency in mammospheres from Tgfb1 HT MECs overexpressing BRCA1 was similar to that of WT MEC mammospheres (Fig. 5C ). These data indicate that BRCA1 mediates TGFb effects on mammary self-renewal and lineage commitment.
TGFb1 increases BRCA1 by inhibiting miR-182 BRCA1 is posttranscriptionally suppressed by several miRNAs, including miR-182 (28), miR-146a, and miR-146b-5p (28, 29) . We analyzed the expression of these miRNAs as a function of TGFb depletion in MEC, MCF10A cells, and mammary fibroblasts. Notably, inhibition of TGFb ligand or signaling in all cells significantly increased the abundance of miR-182 (Fig. 6 , A to D) but did not affect that of miR-146a or miR-146b-5p (Fig. 6 , E to H) nor that of miR-181a and miR-181b ( fig. S6 ), which have been reported to be modulated by TGFb (30) . In contrast, TGFb treatment of MCF10A cells for as little as 30 min significantly decreased the abundance of miR-182 ( fig. S7A ), concordant with the observed increase in BRCA1 mRNA abundance (Fig. 4G) , which persisted for 4 hours, whereas the abundance of neither miR-146a nor miR-146b-5p was affected ( fig. S7B ).
To test whether miR-182 indeed mediated BRCA1 mRNA abundance, we used a lentiviral miRZip to inhibit miR-182 function in MCF10A cells. Stable MCF10A cell lines were established that expressed a miRZip-182 or a scrambled (SCR) miRZip. Expression of miR-182 mRNA was reduced by about half in cells transfected with miRZip-182 (Fig. 7A) , whereas the abundance of transcripts of BRCA1 and FOXO3, another validated miR-182 target, increased severalfold (Fig. 7, B and C) . Infection of Tgfb1 WT and HT MECs with miRZip-182, but not the miRZip-SCR, abrogated TGFb induction and LY364957 suppression of both BRCA1 (Fig. 7D ) and FOXO3 mRNA abundance (Fig. 7E) . These data confirm that miR-182 targets both mRNAs as reported (31) and demonstrate the requirement for miR-182 in TGFb-mediated regulation of BRCA1.
We next compared the HT MEC expression of miRZip-182 or miRZip-SCR to Tgfb1 WT MECs expressing miRZip-SCR. As expected, the miRZip-182 decreased miR-182 to amounts similar to WT MECs and twofold less compared to HT MECs expressing miRZip-SCR (Fig. 7F) . Antagonism of miR-182 also restored Brca1 and Foxo3 protein as assayed by immunoblotting of lysates (fig. S8A) ; their abundance increased in Tgfb1 HT MECs expressing miRZip-182 to levels similar to miRZip-SCR expressing WT MECs and was nearly twice that of miRZip-SCR-infected Tgfb1 HT MECs (Fig. 7G) . These results indicated that TGFb suppression of miR-182 is necessary for BRCA1 mRNA and protein accumulation. If TGFb depletion increases miR-182, which decreases BRCA1 abundance and in turn increases MaSC self-renewal, then antagonizing miR-182 should suppress this phenotype. To test this prediction, we measured self-renewal in MECs by mammosphere formation. The Tgfb1 HT cells expressing miRZip-182 generated half as many mammospheres as Tgfb1 HT cells expressing the control SCR vector (Fig. 7H) . Relative to SCR control mammospheres, miR-182 was reduced in mammospheres of Tgfb1 HT cells expressing miRZip-182 ( fig. S8B) . Moreover, the basal-skewed lineage commitment of Tgfb1 HT mammospheres was reversed (Fig. 7I) , but proliferation was not significantly affected ( fig. S8C) . Together, these studies indicate that TGFb maintains MaSC and lineage commitment by suppressing miR-182 and blocks BRCA1 mRNA degradation. TGFb depletion releases miR-182 to repress BRCA1 mRNA stability or translation, which leads to increased mammary self-renewal and skews lineage commitment to the myoepithelial cell fate. 
DISCUSSION
Our studies demonstrate that autocrine TGFb restricts MaSC expansion and directs mammary lineage commitment to luminal cell fate, which together enforces mammary gland homeostasis. The molecular mechanism underpinning this shift involves stringent control of BRCA1 by TGFb. We determined that TGFb regulates BRCA1 by inhibiting miR-182; miR-182 typically functions to repress BRCA1 protein translation and target its mRNA for degradation. The Brca1 protein level in mammary glands from Tgfb1 HT mice was half of that of TGFb competent mice and was accompanied by a doubling of mammary repopulating cells. We used in vitro mammosphere formation as a surrogate to evaluate the underlying mechanisms of mammary repopulation, which allowed us to ascertain that either Brca1 overexpression or miR-182 antagonism reversed the consequences of genetic depletion of TGFb on self-renewal and lineage commitment. Thus, a TGFb, miR-182, and BRCA1 axis regulate self-renewal and epithelial lineage commitment during mammary homeostasis. The biology of TGFb in the mammary gland is complex [reviewed by Moses and Barcellos-Hoff (32)]. TGFb1 is arguably the most abundant isoform during pubertal morphogenesis, but all three TGFb isoformencoding mRNAs are expressed in the mammary epithelium across all phases of mammary development (33) . The product of each gene is a latent TGFb complex that, when activated extracellularly, releases ligands that bind the same set of receptors. Thus, the key determinant of biological activity is controlled by the latent complex and latency-associated peptide, which are distinctly different for each isoform. We cannot exclude the potential for isoforms to differentially regulate BRCA1 because we did not use reagents to selectively block one isoform, but various studies show that any active TGFb could result in comparable signaling.
The TGFb pathway intersects with multiple miRNAs (34) (35) (36) (37) . Our data in human mammary cell line MCF10A show that TGFb inhibits miR-182, and conversely, TGFb inhibition increases miR-182, whereas neither TGFb addition nor inhibition affects the abundance of miRNAs 146a and 146b (29) or 181a and 181b (38) , which also target BRCA1 mRNA for degradation. The amount of miR-182 is increased in breast tumors compared with normal breast tissue (39) and in serum of patients with breast cancer (40) . High miR-182 is associated with worse outcome in a meta-analysis of 10 studies (41). Overexpression of miR-182 increases the sensitivity of breast cancer cell lines to poly(adenosine 5′-diphosphate-ribose) polymerase 1 inhibitors (28, 42) , similar to that observed in BRCA1-deficient cells and tumors (42) .
The luminal progenitor population is expanded in the haploinsufficient nonmalignant tissue of BRCA1 mutation carriers (19, 20) , whereas engineered deletion of BRCA1 in human cells leads to stem cell expansion (18) . miR-182 is increased in human luminal progenitors compared to MaSCs (43) , which our data suggest might be due to reduced TGFb activity or signaling. TGFb inhibition also significantly increases colony formation of basal cells, which can have mammary repopulating capacity (44) . A paracrine mechanism by which hormone-responsive luminal epithelial cells restrict the expansion of MaSCs (45) may also be reinforced by TGFb because TGFb activation in estrogen receptorpositive luminal epithelial cells inhibits their proliferation at estrus and thus the number of estrogen receptor-positive cells (3, 4) .
The frequency of MaSCs and the subsequent development of aggressive breast cancer are thought to be functionally linked by the cell-of-origin hypothesis, which posits that malignant transformation of long-lived MaSCs or progenitors underlies the heterogeneity of tumor subtypes [reviewed by Visvader (16) ]. For example, women with germline mutations of BRCA1, which was the first genetic locus associated with familial breast cancer risk (46) , have an extremely high risk of developing breast carcinomas negative for estrogen receptor, progesterone receptor, and HER2 amplification; these so-called triplenegative breast cancer occurs at a young age and generally have a very poor prognosis. BRCA1 knockdown in primary breast epithelial cells increases the proportion of stem or undifferentiated cells and decreases the proportion of cells expressing luminal epithelial markers and estrogen receptor (18) . Even before cancer onset, the breast tissue of BRCA1 mutation carriers contains a disproportionate number of luminal progenitor cells (19) and exhibits aberrant progenitor cell lineage commitment (20) . Thus, the prevalence of triple-negative breast cancer per se is linked to aberrant mammary lineage commitment (18) (19) (20) . The effect of radiation on MaSCs and the development of Data are means ± SEM from three biological replicates; *P < 0.05, **P < 0.01, ***P < 0.001, Student's t test.
aggressive cancer are also highly correlated as a function of TGFb in murine mammary carcinogenesis studies (21, 47, 48) . These studies provide substantial support for the idea that dysregulation of stem and progenitor cells during development is involved in the etiology of breast carcinogenesis.
MATERIALS AND METHODS
Mice
All animal experiments were performed at the New York University School of Medicine with institutional review and approval. BALB/c mice were purchased from Taconic and housed four per cage with LabDiet 5008 chow and water provided ad libidum. Tgfb1 HT BALB/c mice were bred in-house under similar conditions. For assays assessing MaSC activity, cells were isolated from five to eight 15-week-old WT or Tgfb1 HT BALB/c mice. Neutralizing antibody 1D11 (R&D Systems Inc.) or isotype control antibody IgG1 (R&D Systems Inc.) was administered by intraperitoneal injection (10 mg/kg) twice a week for 4 weeks. Mammary repopulation capacity was assayed by limiting dilution (23) using five cell doses and 58 mice as recipients per treatment (23) . The repopulating capacity was calculated using L-Calc version 1.1.1 (STEMCELL Technologies). − phenotypes, respectively, as previously reported (17) . Cells were also isolated using the CD49f antibody (BD Pharmingen) and the CD24 antibody as previously described (49) .
Flow cytometry
MECs were also sorted after staining with rabbit-raised antibody against K14 at 1:100 dilution (Covance) and guinea pig-raised antibody against K8/18 at 1:500 dilution (Fitzgerald) overnight. Before staining, cells were fixed in cold 80% methanol. MECs were incubated for 1 hour at room temperature with secondary antibodies Alexa 488-conjugated donkey anti-rabbit IgG and Alexa 594-conjugated donkey antibody recognizing mouse 
Cell culture
MECs and mammary fibroblasts were isolated from 15-week-old nulliparous Tgfb1 WT and HT BALB/c female mice as previously described (23) . Fibroblasts were cultured in Dulbecco's modified Eagle's medium/F12 supplemented with 10% fetal calf serum, penicillin (100 IU/ml), streptomycin (100 mg/ml), L-glutamine (4 mM), bovine pancreatic insulin (5 mg/ml), cholera toxin (10 ng/ml), and epidermal growth factor (EGF) (10 ng/ml). Cells were passaged by differential trypsinization until fibroblasts spontaneously immortalized. Fibroblasts were serum-starved and then cultured in serum replacement medium for 1 day for cell cycle synchronization, and then qRT-PCR and immunostaining assays were performed. MCF10A cells (American Type Culture Collection) were cultured in serum-free medium in the presence or absence of recombinant human TGFb1 (2 ng/ml; R&D Systems Inc), the TGFb type I receptor kinase inhibitor LY364947 (2 mM; Calbiochem), the TGFb neutralizing antibody 1D11 (10 mg/ml), or IgG1 isotype control (R&D Systems Inc,) added at the time of plating and with medium change every other day thereafter, as previously described (50) . The number of cells plated under each condition was selected so that all cultures reached similar degrees of confluence at experiment termination.
Mammosphere culture
MECs were dissociated into single cells according to standard protocol and cultured in mammosphere medium consisting of Epicult-B medium (STEMCELL Technologies) containing 5% Matrigel, EGF (10 ng/ml) (Sigma), basic fibroblast growth factor (20 ng/ml) (BD Biosciences), heparin (4 mg/ml) (Sigma), 5% heat-inactivated fetal bovine serum, and ROCK inhibitor Y-27632 (5 mM) (Tocris) (24) . Cells were seeded at 1000 to 2000 per well in 96-well ultralow attachment plates (Corning). The number of solid appearing mammospheres (diameter >50 mm) was counted 7 days after seeding. Mammospheres were treated in vitro with the TGFb neutralizing antibody 1D11 (10 mg/ml), IgG1 isotype control antibody, or LY364947 (2 mM). Mammospheres pretreated for 1 week were dissociated, and limiting dilutions were seeded into secondary passage without further treatment to measure self-renewal using L-Calc version 1.1.1 (STEMCELL Technologies).
Immunofluorescence and image acquisition Sections (3 or 5 mm) of formalin-fixed, paraffin-embedded mammary gland tissue were deparaffinized, incubated with antigen unmasking solution (Vector), blocked with 0.5% casein, and incubated with primary antibodies overnight at 4°C using mouse p63 antibody (1:100, Lab Vision), rabbit Ki-67 antibody (1:1000, Novocastra NCL-Ki67p), rabbit K14 antibody (1:1500, Covance), guinea pig K8/18 antibody (1:200, Fitzgerald), or mouse phosphorylated Ser 465/ Ser 467 SMAD2 (1:50, p-SMAD) antibody (clone 138D4, Cell Signaling cat. #3108). Slides were washed three times with phosphate-buffered saline and incubated for 1 hour at room temperature with Alexa 488-conjugated donkey antibody recognizing rabbit and Alexa 594-conjugated donkey antibody recognizing mouse (Invitrogen). DAPI was used for nuclear counterstaining, and samples where mounted with VECTASHIELD (Vector).
Ten mammospheres per treatment in each experiment were randomly imaged using 20× and 40× objectives with a numerical aperture of 0.95 Zeiss Plan-Apochromat objective on a Zeiss Axiovert microscope equipped with epifluorescence. For image analysis, 12-bit images for each color channel were used with macros developed in-house from the open source platform Fiji-ImageJ (National Institutes of Health) (51) . The DAPI channel was used to generate the region of interest (ROI) containing the whole area of each mammosphere. The total number of cells per ROI was estimated dividing the area of the ROI by an estimate of the nuclei area, a calculated mean of 150 measured nuclei areas. Finally, an estimated frequency was calculated using the following formula: p63 counted cells per ROI/total estimated cells per ROI × 100.
Quantitative transcript analysis RNA was extracted from epithelial preparations by using the TRIzol reagent (Invitrogen). Complementary DNA (cDNA) was synthesized from 1 mg of RNA using the SuperScript III First-Strand Synthesis System (Invitrogen). Quantitative real-time polymerase chain reaction (qRT-PCR) was performed using SYBR Green Mix (Applied Biosystems) according to the manufacturer's instructions. Primers (table S1) were purchased from Sigma-Aldrich. The amount of genes of interest were normalized against expression of SPARC and analyzed with the comparative C T method for quantitation of transcripts.
Western blotting
Lysates were obtained from MCF10A cells, log phase murine mammary fibroblasts, snap-frozen murine mammary glands cleared of muscle and lymph nodes, or MECs transferred into modified RIPA lysis buffer [50 mM tris (pH 8.0), 150 mM NaCl, 5 mM EDTA, and 1% NP-40] with protease and phosphatase inhibitor cocktails (Sigma-Aldrich). Protein extracts (100 mg) were electrophoresed and transferred to a membrane. BRCA1 was detected using antibodies that target its N terminus (BRCA1-N; a gift from L. A. Chodosh at the University of Pennsylvania) or C terminus (C20, Santa Cruz Biotechnology), and p-SMAD2 at 1:500 dilution (clone 138D4, Cell Signaling Technology cat. #3108). Relative densitometry of the bands was normalized to the densitometry of actin (the loading control) and detected using the LI-COR Odyssey system. miRNA qRT-PCR Total RNA was extracted using TRIzol reagent (Invitrogen) or the miRNeasy Mini Kit (Qiagen). qRT-PCR analysis of mir-182, mir-146a, and mir-146b-5p was performed using the miRNA-specific TaqMan MicroRNA Assay Kit (Applied Biosystems); 12.5 ng of total RNA was reverse-transcribed using the corresponding RT Primer and the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems). PCR was performed on 1.33 ml of RT products by adding the TaqMan PCR primers and the TaqMan Universal PCR Master Mix (Applied Biosystems). SNO and RNU44 small RNAs were used for normalization of input RNA/cDNA amounts.
Stable overexpression in cultured cells
The BRCA1 (Ex-H0047-Lv105) and control (EX-NEG-Lv105) vectors were purchased from GeneCopoeia, and lentiviruses were prepared according to the manufacturer's protocol. Virus-containing medium was centrifuged, filtered (0.45 mM polyethersulfone low-protein filter), and stored at −80°C. WT MECs or Tgfb1 HT MECs were diluted into low-attachment plates to obtain mammospheres that were then dissociated and seeded as single cells in mammosphere medium containing 5% Matrigel as described above. Cells in mammosphere medium were infected with concentrated virus-containing medium and polybrene (6 mg/ml). Twenty-four hours after transfection, medium containing virus was removed and replaced with mammosphere medium. Then, cells were selected with puromycin (1 mM) for 2 days to generate mammospheres with stable overexpression of WT BRCA1. After selection, cells were dissociated and seeded by limiting dilution in 96-well low-attachment plates to assess the MFE.
Lentiviral antisense miR-182 (miRZip-182), control vectors, and packaging plasmids were generated as described (52) . Stable expression of miRZip-182 in MCF10A was achieved through lentiviral infection. Cells were growing exponentially before transduction and infected at 70 to 80% confluent state. Stable expression was achieved through selection in puromycin (1 mg/ml) (Gibco A1113803, Thermo Fisher Scientific). Infection of lentiviral vectors was undertaken in the presence of polybrene (6 mg/ml) (H9268, Sigma-Aldrich). Fresh medium with puromycin (1 mg/ml) was replaced every 2 days. Medium without puromycin was used for experiments. For qRT-PCR assay, TGFBR1 kinase inhibitor LY364947 (2 mg/ml) was given 20 hours before TGFb treatment (2 ng/ml, 240-B-002, R&D Systems Inc). Cells were then lysed using QIAzol (79306, Qiagen) 4 hours after TGFb treatment. Total RNA was extracted with miRNeasy Mini Kit (217004, Qiagen).
Oligonucleotide miRZip transfection
Tgfb1 WT MECs and HT MECs were seeded in 12-well plates and transfected with miRZip-182 or SCR miRZip-negative control oligonucleotides (150 nM) (miRIDIAN, Applied Biosystems) using Lipofectamine 2000 (Invitrogen) in triplicate, according to the suggested manufacturer's procedures. Transfection efficiency was monitored using Renilla luciferase.
Statistics
Data are presented as means ± SEM from three biological replicates conducted with three technical triplicates, unless noted otherwise. Differences between treatment groups were determined using c² test (FACS), two-tailed Student's t test (comparison between two groups or treatments), or one-way ANOVA (comparison between three groups or treatments). Results were considered statistically significant at P < 0.05.
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